The anti-tumor effect of low doses of IM (~10−7 M) is mainly mediated by the activation of protein kinase C (PKC) and the PKC-dependent release of proinflammatory cytokines and chemokines, and thus, the activation of endothelial and immune cells [20,21]. The gene discussed is PRRT2; the disease is neoplasm.